In the last trading session, 6.6 million Revance Therapeutics Inc (NASDAQ:RVNC) shares changed hands as the company’s beta touched 0.82. With the company’s per share price at $4.13 changed hands at $0.68 or 19.71% during last session, the market valuation stood at $433.24M. RVNC’s last price was a discount, traded about -135.84% off its 52-week high of $9.74. The share price had its 52-week low at $2.30, which suggests the last value was 44.31% up since then. When we look at Revance Therapeutics Inc’s average trading volume, we note the 10-day average is 2.96 million shares, with the 3-month average coming to 4.79 million.
Analysts gave the Revance Therapeutics Inc (RVNC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.78. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RVNC as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Revance Therapeutics Inc’s EPS for the current quarter is expected to be -0.29.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Revance Therapeutics Inc (NASDAQ:RVNC) trade information
Instantly RVNC was in green as seen at the end of in last trading. With action -29.28%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -53.01%, with the 5-day performance at -29.28% in the red. However, in the 30-day time frame, Revance Therapeutics Inc (NASDAQ:RVNC) is -19.65% down. Looking at the short shares, we see there were 9.19 million shares sold at short interest cover period of 2.72 days.
The consensus price target for the stock as assigned by Wall Street analysts is 17.5, meaning bulls need an upside of 76.4% from its current market value. According to analyst projections, RVNC’s forecast low is 6.66 with 37 as the target high. To hit the forecast high, the stock’s price needs a -795.88% plunge from its current level, while the stock would need to soar -61.26% for it to hit the projected low.
Revance Therapeutics Inc (RVNC) estimates and forecasts
Data shows that the Revance Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 18.68% over the past 6 months, a 59.01% in annual growth rate that is considerably higher than the industry average of 17.10%. Year-over-year growth is forecast to reach 14.80% up from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of 79.09M. 2 analysts are of the opinion that Revance Therapeutics Inc’s revenue for the current quarter will be 69.3M. The company’s revenue for the corresponding quarters a year ago was 69.8M and 51.94M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 13.30%. The estimates for the next quarter sales put growth at 33.40%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.57%. The 2024 estimates are for Revance Therapeutics Inc earnings to increase by 45.99%, but the outlook for the next 5-year period is at 11.60% per year.
RVNC Dividends
Revance Therapeutics Inc is expected to release its next quarterly earnings report in December.
Revance Therapeutics Inc (NASDAQ:RVNC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 8.52% of Revance Therapeutics Inc shares while 71.61% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 78.28%. There are 71.61% institutions holding the Revance Therapeutics Inc stock share, with CAPITAL WORLD INVESTORS the top institutional holder. As of 2024-06-30, the company held 15.164% of the shares, roughly 13.94 million RVNC shares worth $35.82 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 9.3183% or 8.57 million shares worth $22.01 million as of 2024-06-30.
